Hiển thị tất cả

ACIP: US changes to vaccine guidance and recommendations

The American Advisory Committee on Immunization Practices (ACIP) met recently, voting to change MMRV and COVID-19 vaccine guidelines and recommendations, and postponing a vote on proposed changes to hepatitis B vaccination.

The combination measles, mumps, rubella and varicella vaccine (MMRV) is no longer recommended in the US for children under 4 years of age. The COVID-19 vaccine is no longer recommended for all adults in the US; recommendations are now subject to a ‘shared decision-making’ process whereby individuals are advised to weigh up risks and benefits with a healthcare professional.

Via our social media platforms, MVEC has published a shortform explainer (@mvecau on Instagram) on ACIP’s MMRV change and why it shouldn’t impact confidence in Australia’s immunisation program. 

Materials from the 18 to 19 September meeting are not yet fully accessible for all audiences.  

The following articles from US-based publications offer more context on the ACIP meeting:

NPR: CDC advisers punt on hepatitis B vaccine vote, after changing guidance on MMRV
ABC News: Why doctors say the birth dose of the hepatitis B vaccine is still necessary

For more information on the relevant vaccine-preventable diseases, go to:

MVEC: Sởi
MVEC: Varicella
MVEC: COVID-19
MVEC: Viêm gan B

qua Alice đen

States offering nasal spray influenza vaccine in 2026

New South Wales, Queensland and South Australia have announced free nasal spray influenza vaccine programs for young children. Already widely used overseas, the FluMist intranasal vaccine is undergoing regulatory approval in Australia ahead of next year’s flu season. 

The state programs will cover children aged between 2 and 5 years. The regular injectable influenza vaccine remains free nationwide for all children aged 6 months to < 5 years. 

Read more on each state program here:
New South Wales: Free nasal spray influenza vaccine for children under five
Queensland: 2026 Queensland Nasal Spray Flu Immunisation Program
South Australia: Needle-free flu vaccine for SA children 

Read more about influenza disease and immunisation at MVEC: Cúm

qua Alice đen

NEJM: Clesrovimab for prevention of RSV disease in healthy infants

A recent trial has shown that a single dose of the monoclonal antibody clesrovimab reduced the incidence of RSV-associated lower respiratory infection and RSV-associated hospitalisation in healthy preterm and full-term infants. 

Clesrovimab demonstrated 60% efficacy in reducing medically attended RSV-associated lower respiratory infection and 84% efficacy in reducing RSV-associated hospitalisation. The adverse-event profile of clesrovimab was similar to that of placebo. The authors note that rare serious adverse events may not be detected in a trial of this size (3632 infants). 

Read the paper in full: NEJM: Clesrovimab for prevention of RSV disease in healthy infants

Read more about respiratory syncytial virus (RSV) at MVEC: RSV

qua Alice đen

New York Times: The playbook used to ‘prove’ vaccines cause autism

The New York Times recently published an essay written by public health expert and science communicator Dr Jess Steier. Focusing on the work of vaccine critic David Geier, Dr Steier breaks down the “anti-vaccine research playbook” to help people spot flawed science.

Read the article in full at NYT: The playbook used to ‘prove’ vaccines cause autism

Read more on autism and vaccination on MVEC: Autism and immunisation

qua Alice đen

Victorian Department of Health: New measles alert

Các Victorian Department of Health has issued a new health alert following a new measles case in Victoria. The alert includes an up-to-date list of public exposure sites in Victoria. 

Read the alert in full at the department’s page Health alerts: New measles case in Victoria. 

Learn more about measles disease and vaccination at MVEC: Sởi 

And check out MVEC director Prof Nigel Crawford’s May 2025 Healthed article Và podcast, which both cover the current measles resurgence. 

qua Alice đen